__________________ Effective Management of Acute and Chronic Pain with Opioid Analgesics, 2nd Edition
F inal E xam
EFFECTIVE MANAGEMENT OF ACUTE AND CHRONIC PAIN WITH OPIOID ANALGESICS
Select the best answer for each question and mark your answers on the Final Examination Answer Sheet found on page 75, or complete your test online at BOOK.CME.EDU. A passing grade of at least 70% must be achieved in order to receive credit for this course.
1. Nonpharmacologic and self-management treatment options have been found to be effective alone or as part of a comprehensive pain management plan for (A) Nociceptive and neuropathic pain (B) Acute pain >48 hours after tissue trauma
6. Which of the following is a possible reason for prescribing naloxone to a patient who has been prescribed an opioid analgesic? (A) The patient is taking a dose of an opioid >50 MMED. (B) The patient has recently entered prison. (C) The patient has history of hypertension. (D) The patient has a concurrent prescription for an SSRI antidepressant. 7. According to the Centers for Disease Control and Prevention, what amount of opioid analgesic is appropriate for most painful conditions?
(C) Neuropathic and chronic pain (D) Musculoskeletal and chronic pain
2. What is the maximum recommended daily dose of acetaminophen for healthy adult patients?
(A) 2,500 mg (B) 3,000 mg (C) 3,500 mg (D) 4,000 mg
(A) 2-day supply (B) 3-day supply (C) 5-day supply (D) 7-day supply
3. Which nonopioid analgesic has been successfully used to treat such acute pain conditions as sickle cell crises, renal colic, and trauma?
8. Which of the following medications is a full mu- receptor agonist used to treat opioid use disorder? (A) Methadone (B) Buprenorphine (C) Extended-release naltrexone (D) Naloxone 9. Which of the following medications can be self- administered by patients with a medication obtained from a regular pharmacy? (A) Methadone (B) Buprenorphine (C) Extended-release naltrexone (D) Naloxone 10. For which of the following must clinicians obtain a special waiver from the DEA prior to being able to prescribe the medication? (A) Methadone (B) Buprenorphine (C) Extended-release naltrexone (D) None of the above
(A) Ketamine (B) Cannabis (C) Capsaicin (D) Anticonvulsants
4. Which of the following topics should be routinely covered as part of patient education about opioid analgesics? (A) Background information about acute vs. chronic pain (B) Criteria for opioid use disorder (C) Safe medication disposal (D) Difference between nociceptive and neuropathic pain 5. Which of the following is an example of a functional goal? (A) Reduced anxiety about pain (B) Reduced need for rescue analgesia (C) Reduced daily dose of opioid analgesic (D) Resumed sexual relations
Test questions continue on next page
51
MDUT1125
Powered by FlippingBook